Nuo Therapeutics Inc.
AURX
Corporate Overview Nuo Therapeutics, Inc. is a Delaware corporation organized in 1998 under the name Informatix Holdings, Inc. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$5M
▲ +142.7% YoY
Net Income (TTM)
-$2M
▼ -8.1% YoY
Op. Margin
-33.32%
▲ +104.1pp YoY
ROIC
-1559.40%
▼ -316.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▲ +52.2% YoY
Op. Cash Flow (TTM)
-$2M
▲ +61.2% YoY
Net Debt
-$389K
Net Cash Position
Cash & Equiv.
$449K
Continue Research
Peers
Surgical & Medical Instruments & Apparatus · Pick stocks to compare with AURX
Nuo Therapeutics (AURX) in four numbers
Questions about Nuo Therapeutics
Is Nuo Therapeutics (AURX) overvalued?
At $1.07, Nuo Therapeutics' price is 71% below the $3.71 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Nuo Therapeutics' fair value?
Intrinsiqq's calculator puts Nuo Therapeutics' fair value at $3.71 a share. It grows revenue per share 30% a year for 5 years, applies an exit P/S of 15, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $2.78. Every input can be changed on the Intrinsic Value tab.
Is Nuo Therapeutics a high-quality business?
Nuo Therapeutics scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 160.9%, and its weakest is return on capital at -1559.4%. The Quality tab shows every check against its target.
Does Nuo Therapeutics (AURX) pay a dividend?
No. Nuo Therapeutics (AURX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 5 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in AURX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AURX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.